Abstract Although the cancer research community has supported a ''nondisclosure'' position about the return of individual results to research subjects, new technologies, such as genome wide association studies, will reveal clinically relevant findings, some of which cannot be ignored. What recommendations exist that can guide researchers and Institutional Review Boards (IRBs) about this issue? This article summarizes the relevant public documents about the disclosure of individual research results to inform policy development. Four stakeholder groups were selected to make this comparison: federal, professional, advisory, and advocacy groups. Regardless of a group's position on disclosure, there was consensus that if research results were to be disclosed under any condition, the results must be analytically and clinically validated and that the researcher should not make this decision alone, but in conjunction with the IRB. There was no consensus, however, on the specific determinants for disclosure or what constitutes clinical validity. Although sufficient agreement exists to begin developing general guidelines about the process for disclosure of individual research results, the actual determinants with which to guide this decision remain challenging. An alternate framework that addresses the threshold of uncertainty a stakeholder is willing to accept, the positive predictive value of the research finding, and the magnitude of harm of returning results may be more effective to guide decision making. These assessments, along with what is considered useful information, requires the involvement of the research subject community to inform decision-making and move the policy process forward.
Setting the Stage
The recent NIH Policy for GWAS suggests that the researcher and her/his IRB or designated institutional official are expected to devise a plan to address the possibility of revealing clinically relevant information identified through the course of genomic research. 1, 2 This suggestion has moved the controversial issue of disclosure of individual research results to the forefront of cancer research, not only for GWAS but for the entire spectrum of cancer research studies. Currently, many issues remain unclear, including the conditions that warrant disclosure of individual versus aggregate research results, how to handle findings unrelated to the original research, who should make these decisions, and who should be responsible for communicating findings to the research subject. Researchers and IRBs need guidance to help address these issues and develop responsible, consistent policies to protect the rights and welfare of research subjects, and to engender the public's trust in the research enterprise. For more than a decade, many professional, federal, advisory, and advocacy groups have presented guidelines or recommendations to address issues of disclosure of individual research results. What can we learn from these efforts? The purpose of this article is to review and comment on results from a systematic analysis of the existing recommendations, present a set of guidelines on the basis of areas of consensus, and identify next steps to facilitate policy development and translation into practice.
Consider the following scenario: An investigator conducting a GWAS in newly diagnosed breast cancer patients uncovers a polymorphism recently reported to be associated with a lethal toxicity to a certain class of drugs. The polymorphism is observed in 5% of the study patients, and the class of drugs is related to current treatments for neutropenia. What should the investigator do with this information? What if the toxicity were not lethal? Is the researcher responsible for communicating these findings to the research subject or the treating clinician? (Table 1) . 1 NIH Guidance for Developing Data-Sharing Plans for GWAS (2007) . Available from: http://grants.nih.gov/grants/gwas/gwas__ data__ sharing__ plan.pdf. 2 The above scenario, although currently rare, is likely to increase in frequency as researchers worldwide generate data and gain access to a growing resource of large specimen banks and linked databases containing genotypic and phenotypic profiles in diseased and healthy populations (e.g., dbGAP, caBIG, PharmGkb). 3 Access to this information, coupled with the expansion of efficient and reliable tools at lower costs, such as whole genome sequencing, will offer unparalleled potential to integrate vast amounts of information to understand etiology, progression, and treatment of cancer. Some information revealed in these efforts will have substantial health or clinical value.
Arguments for and against Disclosure
Given the nature of these issues and the involvement of multiple stakeholders (research subjects, advocacy groups, IRBs, clinicians, researchers, funding agencies, the public, etc.) with different and sometimes conflicting interests, it is not surprising to find strong arguments on both sides of the disclosure issue (Table 2) . Nor is it surprising to find national guidance lacking.
Traditionally, cancer researchers in the United States have favored release of aggregate but not individual results (1 -3) . This position has been justified for several reasons. First, researchers seek to protect research subjects from potentially harmful consequences of receiving preliminary or unconfirmed research results, including false reassurances or unnecessary scares. 4, 5 Second, clinician-researchers seek to distinguish and keep separate the professional role of scientist from the fiduciary role of clinician. Third, federal law restricts the use of information, including research results, in treatment decisions unless the test is done in a CLIA-approved laboratory 6 (Clinical Laboratory Improvement Amendments). Finally, because the intent of research is to provide generalizable knowledge, not necessarily to benefit an individual research subject, the return of individual research results is contrary to this perspective. It should be noted, however, that return of aggregate results is still an uncommon practice in the United States, even though cancer patients have indicated a desire for this information (4, 5).
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There is an evolving ethic, however, especially at the international level, that challenges the traditional nondisclosure argument in the United States and promotes the return of individual research results, specifically in the context of genetic and genomic studies (6) . The Council for the International Organization of Medical Sciences (CIOMS) guidelines stipulate that after study completion, subjects will be informed of findings related to their particular health status. 8 Proponents of this position view research participants as equal partners in the research enterprise and recognize that some research results may have value to the research subject, such as empowerment or proactive lifestyle changing behaviors (7, 8) . 9 Communication of research results can also be viewed as preventing harm, especially ''when the research information provides evidence of immediate risk to the individual and there is an intervention available to ameliorate the risk.'' 9 At the same time, disclosure is not supported when doing so would predictably compromise
Translational Relevance
With the emergence of newer and cheaper technology to scan an individual's genome, the likelihood increases that clinically relevant research results will be revealed. This, coupled with the recent National Institutes of Health (NIH) genome-wide association studies (GWAS) policy suggesting that researchers and Institutional Review Boards (IRBs) have a plan to manage this occurrence, has moved the controversial issue of return of individual research results to the forefront of cancer research. A key factor in the development of determinants for disclosure is consistent criteria for determining clinical validity and the involvement of the research subject community to assess what constitutes useful information to be returned. This article presents the arguments for and against disclosure, reviews the existing recommendations from federal, advisory, professional, and advocacy groups related to disclosure of results, and identifies common themes and remaining challenges for policy development. 6 CLIA: Clinical Laboratory Improvement Amendments of 1988. Pub. L. No. 100-578 102 Stat.2908. CLIA. approved laboratories are approved for general quality control and quality assurance practices; the approval process does not necessarily extend to review and approval of the performance of individual tests, genetic or otherwise. Available from: http://www.fda.gov/CDRH/clia/pl100-578.pdf. 7 Most aggregate results are returned to research subjects in the form of a technical article or abstract and usually following the request of the individual or family. Results of NIH funded studies are also now available to the public on PubMed Central.There are efforts afoot by advocacy and some clinical trials groups to develop lay summaries of research studies to be available by internet, newsletter, or regular mail. 8 the safety of the research subject or third party (7) . Mindful of the limitations and unpredictable nature of research results, there remains growing confidence, especially in the international setting, of the utility of research findings, which are increasing at an exponential pace, and the resulting optimism of their rapid translation into clinical practice. These perspectives fuel arguments in favor of release of individual research results. 10 Between 1990 and 2008, various groups have presented numerous recommendations and guidelines about the disclosure of individual research results. A systematic review of relevant public documents formed the basis for the summary in this article. The review is not meant to include all possible articles, but to be thorough enough to reach saturation of the major issues as described below.
Learning from Existing Recommendations
Positions of professional, federal, regulatory, advisory, and advocacy groups Professional, federal, regulatory, advisory, and advocacy group positions vary greatly on the issue of disclosure of individual research results, ranging from never disclose to always disclose (Table 3 ). The National Action Plan on Breast Cancer (NAPBC) 9 , a group composed of breast cancer patient advocates, National Cancer Institute (NCI) representatives, scientists, and others, supports the routine disclosure of genetic research results to participants, whereas both the National Bioethics Advisory Commission (NBAC) 5 and Office of Human Research Protections (OHRP), formerly Office of Protection of Research Risks (OPPR), only support disclosure of genetic research results in rare circumstances. 4 NAPBC asserts however, that providing research results that do not meet CLIA and other validity requirements (i.e., analytic and clinical validity) increases risks and may cause ''erroneous conclusions to be made that could result in physical, psychosocial or economic harms.'' 9 NBAC and OHRP/OPPR indicate that research data require independent confirmation and a statistically valid study design to associate a research finding with clinical significance. Neither the Common Rule nor the HIPAA Privacy Rule offer guidance about the return of individual research results. 11 According to Amdur's IRB member handbook, there is no ethical requirement to disclose individual research results per se, unless the researcher has indicated such in the informed consent process (7). However, a report by the Department of Energy (DOE) 12 indicates that ''the disclosure of individual research results represents the greatest risk to research participants involved in genetic research studies,'' citing risks of stigmatization and discrimination beyond health insurance and employment to include life insurance, creditors, and educational institutions. 12 The American Society of Human Genetics (ASHG) (9), National Human Genome Research Institute (NHGRI), 13 and National Heart Lung and Blood Institute (NHLBI) (10) include more detailed guidance for disclosure, supporting such action only in certain contexts or if the case meets specified criteria (see Table 4 ).
Despite the range of positions of these groups, there was consensus that if research results are to be disclosed under any circumstances, the results must be analytically and clinically validated. Several other common themes have emerged in both process and conditions for disclosure of individual research results (Tables 3 -5) .
Responsible party to determine whether to disclose. Most groups include the IRB with or without the input of the research investigator in the decision-making process about the disclosure of individual research results (Table 3 ). There was no consensus, however, on how this decision-making process would unfold and who else would need to be involved in making this decision. NBAC, OHRP/OPPR, and NHGRI place the burden on the researcher to indicate the intent to disclose or withhold in the informed consent process. NBAC additionally requires the investigator to justify the intent to disclose in the IRB application. 5 NBAC, NIH GWAS policy, and NHGRI recommend that the investigator, working with the IRB, have a management plan for the potential occurrence when individual research results would be disclosed. 2, 5, 13 The NIH GWAS policy suggests that the IRB have a management plan to address not only return of results generated by the primary investigator but also return of results generated by a secondary investigator who would be responsible to contact the primary investigator with a clinically relevant finding. 2 Individual to give the results to the research subject. Nearly every group indicated that a medical professional trained in genetic counseling should give the results (e.g., medical geneticist, genetic counselor, medical professional trained in genetic counseling) ( Table 3) .
Process for disclosure of results. There was consensus that professional (genetic) counseling prior to and after communicating research results should be provided. The cost of this counseling, however, is still an issue. NHLBI indicated that participants should be responsible for the cost (10), whereas other groups (NAPBC) advocate that this cost should be covered in the research budget. 9 Informed consent requirements. There was unanimous agreement that if disclosure of individual results were intended or possible, the informed consent process must not only state this, but also include a description of the risks associated with the disclosure. Most groups acknowledged that such risks should include a description of psychosocial risks 9 (10) including disruption of family dynamics, possible reproductive implications (9, 11) , stigmatization, and economic risks, such as potential to compromise insurability in life and health insurance, or employability by misuse of the disclosed findings. In the context of disease susceptibility studies, both ASHG and NHLBI underscore that factors such as uncertainty of disease prediction and magnitude of severity of disease must be part of the risk discussion. NAPBC and OHRP/OPPR suggest that misidentified parentage not be disclosed.
Oversight of the process for determining disclosure and communicating results. Nearly every group indicated the need for an oversight process to ensure that appropriate decisions are being made in an efficient and ethical manner. NAPBC's oversight process includes maintaining up-to-date information on clinically relevant findings revealed through the course of a study and the validation of such findings by other independent investigators. NBAC seeks to ensure that these findings are assessed by the oversight group and communicated to the research participant when warranted. Similar to the NIH GWAS policy, many of the groups put the onus on the IRB to develop a set of guidelines for when disclosure of results was appropriate and a process or management plan for this inevitable scenario. Yes, except in certain circumstances (see Table 4 ).
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No, except in rare circumstances.
Maybe, depends on study. Respect right to know, and right not to know research results.
No, except when a treatment exists to improve the diagnosis.
Yes, if they meet certain criteria (see Table 4 ). Conditions for Disclosure Requirement for analytic and clinical validity. All groups agreed that research results should be analytically and clinically validated as conditions for returning research results to research subjects. Even the NAPBC, which supports the routine disclosure of experimental data, is clear in its position that ''in the absence of clinical validity there should be no requirement for data to be returned to subjects.'' 9 NHGRI echoes the criteria developed by NAPBC (Table 4 ). Both groups (NAPBC and NHGRI) indicate that IRBs need to judge the data worthy of communication to the research subject. If IRBs have determined, at the time of protocol submission, that research results will not be returned, the informed consent must explicitly state this. 13 Requirement for medical intervention. In addition to clinical and scientific validity, NBAC requires that ''a course of action is available to ameliorate or treat the health concern''. 5 NBAC's position reflects the current perspective of OHRP/OPPR, NHLBI, and much of the clinical cancer research community that, in addition to clinical validation of the result, an intervention needs to be available to warrant disclosure. This position, common among many professional and regulatory groups, is not shared by some advocacy groups, or ASHG (9), especially in noncancer related contexts (e.g., Huntington's Disease, Alzheimer's disease), which support a right to know regardless of the availability of an intervention.
Consideration of relative risk and gene penetrance for genetic results. The NHLBI (10), focusing specifically on the release of genetic research results, includes parameters such as relative risk of the research result to predict the condition or outcome (i.e., RR > 2.0) and prioritizing gene associations with high penetrance or early age of onset in the determination for disclosure ( Table 4) .
Consideration of reproductive factors. Several groups (9, 10, 11) include reproductive decisions as a factor in determining disclosure of results, citing family planning and risk to existing offspring as important issues to consider (Table 4) .
Net benefit to research subject. Recently, the Working Group on Incidental Findings 14 developed a classification system for handling incidental findings discovered in the process of research (11) . They assign rankings to the findings on the basis of expected net benefit to the research subject: strong, possible, or unlikely net benefit. Each category of benefit considers whether the finding confers a life threatening or grave condition, the degree to which the risk can be ameliorated or avoided, and the implications for reproduction (Table 4) . . Consideration of net benefit to research subject.
Common Themes, Remaining Challenges, and Next Steps for Policy Development
This analysis revealed several common themes and areas of consensus, most predominantly related to process issues (Table 5) . These areas of agreement can be used today to move the policy process forward (Table 6 ). They include having the researcher justify in the IRB protocol his or her rationale for disclosing or withholding results; having not the researcher, but a professional trained in genetics and genetic counseling communicate results to the research subject; giving the research subject the opportunity to accept or refuse the opportunity to have research results returned; and in collaboration with the IRB, researchers, and other experts, having a management plan to address the scenario when a clinically relevant finding is discovered of what to do.
Although attaining agreement to process issues is a good first step, many challenges remain. The first main issue is that these areas of agreement do not yet translate into practical guides for decision making. It may be unrealistic to task an already overburdened IRB to develop decision-making criteria about what constitutes analytically and clinically valid research findings and a management plan to communicate results to research subjects. Kohane and colleagues proposed a model, the Informed Cohort Oversight Board (ICOB), to address this issue (12) . The ICOB has an oversight, decision-making, and implementation role, combining features of a clinical Data Safety Monitoring Board (DSMB) with an infrastructure to implement decisions, including tracking and counseling research subjects. The ICOB, composed of a multidisciplinary team of geneticists, genetic counselors, ethicists, statisticians, patients, and communication experts, would identify what information is worthy of being communicated and how best to communicate it to a research subject (12) . A research ethics consultation service (RECS) may also take on a similar role (13) . 15 The RECS or ICOB could partner with the IRB to ensure that decisions and plans for communication are ethical and comply with applicable regulations.
This review illustrates that clinical validity and clinical utility heavily influence the decision to return or withhold individual research results. However, we are faced with a conundrum; no consistent criteria exist for determining when the threshold for clinical validity or utility has been met. According to the Centers for Disease Control and Prevention (CDC), clinical validity refers to the ability of the research assay to predict the associated phenotype, condition, or response to therapy. 16 However, disciplines, groups, and individuals vary in how they determine clinical validity, rendering the possibility of developing consistent criteria questionable. But what if we framed the issue in another way (14) and asked the following question: Under what conditions would it be acceptable to violate the current nondisclosure practice in the United States? Answering this question would require addressing the threshold of uncertainty the different stakeholders (patients, subjects, clinicians, researchers, IRBs, funding agencies) are willing to accept, the degree to which the research findings' predictive value are substantiated, and the magnitude of harm that would result if the prediction is wrong. Addressing these three components may more effectively inform decision making, especially if research subjects are included in the process.
Some may contend that clinical relevance should not be the driving force in decisions about return of individual research results (15) and may not reflect the position of the cancer patient or research subject. This brings us to the second main challenge: the recommendations in this review do not reflect a systematic analysis of the cancer patient's or research subject's perspective. Few studies analyze the concerns, expectations, and positions of cancer patients on the topic of return of individual research results and even fewer relate to cancer genomic data (16) . Although the NAPBC involved breast cancer patient advocates, it is important to understand the position of research subjects who may not be patient advocates and who are participating in current cancer genomic studies. In the United States today, neither aggregate nor individual results are returned (1, 17) . Do research subjects expect the return of research results that are clinically or health related? Research subjects may want to receive this information regardless of the existence of a medical intervention-for making lifestyle changes or for joining a registry. Research subjects may also consider themselves not just patients, but partners in the research process. As research partners, individuals may consider return of results as a form of benefit-sharing or reciprocity not hinging on relevance to health. Is the clinical perspective reflected in the majority of groups reviewed in this study considered appropriate or overly paternalistic? A need exists for empirical studies to address these and other questions to understand research subjects' perspectives and to consider their positions in the conduct of cancer genomic research and development of research policy.
As more cancer researchers probe the genome with better tools (e.g., DNA sequencing), they will more rapidly identify and validate clinically relevant information, resulting in a protracted timeframe for translating clinically useful research information into clinical practice. Our efforts will uncover unexpected findings, some of which cannot be ignored. As the larger amounts of information we amass about individuals become accessible to clinicians and researchers, the line will further blur between whether that information is considered a research result or clinical information. In this setting, research is likely to benefit not only the public, but also the individual research subject, challenging the current philosophy about the purpose of research.
The return of individual research results would require robust infrastructure, including expert personnel, funding, and informatics to appropriately communicate and counsel research subjects, as well as to track their whereabouts. This type of effort would likely not be feasible for an individual investigator and would instead require a centralized mechanism with appropriate 14 '' An IF is a finding concerning an individual research participant that has potential health or reproductive importance and is discovered in the course of conducting research but is beyond the aims of the study.This means that IFs may be onvariables not directly under study and may not be anticipated in the research protocol'' (see ref.11, p. 219). 16 CDC. Office of Public Health Genomics. Evaluation of GeneticTesting. ACCE: A CDC-Sponsored Project Carried out by the Foundation of Blood Research. Available at: http://www.cdc.gov/genomics/gTesting/ACCE.htm. 15 A research ethics consultation service, analogous in some ways to a clinical ethics consult, offer researchers and IRBs help in analyzing ethical issues in the context of research. Some services will provide potential solutions or ethically acceptable options for the researcher and IRB to consider to address the issue. The recent development of research ethics consultation services have been supported through NIH funded Centers of Translational Science Awards (CTSA) and NHGRI funded Centers of Excellence in Ethical, Legal, Social Implications of Genetic Research (CEERS).
oversight and measures to ensure sustainability. At the very least, we should be developing ways to communicate aggregate results to patients and research subjects who want this information (1, 17) .
The next step in developing guidance for decision making in the disclosure of individual cancer genetic and genomic research results requires a deliberative process of consensusbuilding that involves all key stakeholders and is informed by appropriate empirical studies.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed. Table 6 . Recommendations for policy development 1 . IRBs and/or research ethics consultation services should develop guidelines for researchers to assess the likelihood that the study will reveal clinically relevant information and develop policies to guide how these findings should be managed (i.e., whether they should be communicated to the research participant and/or the treating physician). 2. As part of IRB and grant applications, researchers should assess the likelihood that clinically relevant research results, including incidental findings, would be revealed in the study and develop a plan, in collaboration with the IRB, to determine how the findings should be managed. 3. The researcher should indicate and justify in the informed consent process and document whether or not individual research or incidental findings will be disclosed to the participant and their family. 4. The researcher should plan for the release of aggregate data, in the form of plain language summaries, describing in general terms the findings of the study and not rely on the technical manuscript as the means of communication of aggregate results. 5. If individual research results or incidental findings are to be disclosed to the participant, all of the following should apply:
a. The researcher should interact with his/her IRB to determine a management and coordination plan for review, validation, and return of findings. b. The findings must be determined to be analytically and clinically valid and be confirmed in a CLIA approved laboratory or under the supervision of a CLIA approved laboratory. c. The findings must be reviewed by an oversight or DSMB-like committee and deemed appropriate for communication to the research participant. d. The participant be given the opportunity to know or not know the findings. e. The individual communicating the results must be a medical professional with training in genetic counseling.
